-
公开(公告)号：US09487570B2
公开(公告)日：2016-11-08
申请号：US13698819
申请日：2010-05-17
Applicant: Shaojing Hu , Fenlai Tan , Yanping Wang , Cunbo Ma , Yunyan Hu , Hong Cao , Xiangdong Zhao , Wei Long , Yinxiang Wang , Lieming Ding
Inventor： Shaojing Hu , Fenlai Tan , Yanping Wang , Cunbo Ma , Yunyan Hu , Hong Cao , Xiangdong Zhao , Wei Long , Yinxiang Wang , Lieming Ding
IPC: A61K38/26 , A61P3/10 , A61P7/12 , C07K14/605 , A61K38/00 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K9/00
CPC classification number: C07K14/605 , A61K9/0019 , A61K38/00
Abstract: The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.
Abstract translation: 本发明涉及胰高血糖素样肽的新型类似物和可用于上调哺乳动物胰岛素表达和治疗糖尿病的组合物。 特别地，这些肽衍生物具有肽模拟接头并且提供用于治疗糖尿病和其它促胰岛素肽相关疾病，胃肠功能和与胰高血糖素水平相关的活性的长期作用。
-
公开(公告)号：US08742138B2
公开(公告)日：2014-06-03
申请号：US13384097
申请日：2010-07-14
Applicant: Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan , Yunyan Hu
Inventor： Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan , Yunyan Hu
IPC: C07D311/02
CPC classification number: A61K31/37 , C07D311/56 , C07D405/04
Abstract: This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds.
Abstract translation: 本发明涉及可用作缺氧模拟物的新化合物。 本发明还涉及通过向受试者施用这些化合物中的至少一种来提高受试者中HIF水平或活性或治疗与受试者中HIF水平或活性相关的病症的方法。
-
3.发明申请Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors 有权用作c-Met酪氨酸激酶抑制剂的新型稠合杂环衍生物公开(公告)号：US20130123286A1
公开(公告)日：2013-05-16
申请号：US13809836
申请日：2011-07-14
Applicant: Shaojing Hu , Fei Wang , Wei Long , Xiaoyan Shen , Fenlai Tan , Yinxiang Wang
Inventor： Shaojing Hu , Fei Wang , Wei Long , Xiaoyan Shen , Fenlai Tan , Yinxiang Wang
IPC: A61K31/519 , C07D403/04 , A61K31/502
CPC classification number: C07D491/04 , C07D498/04
Abstract: Certain novel fused quinazoline derivatives of formula (I) as c-Met inhibitors, their synthesis and their uses for treating a c-Met mediated disorder. Methods for treating a c-Met-mediated disorder are also disclosed in the invention.
Abstract translation: 式（I）的某些新的稠合喹唑啉衍生物作为c-Met抑制剂，其合成及其用于治疗c-Met介导的病症的用途。 用于治疗c-Met介导的病症的方法也在本发明中公开。
-
4.发明授权Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof 有权盐酸伊替替，合成，结晶形式，药物组合物及其用途公开(公告)号：US08822482B2
公开(公告)日：2014-09-02
申请号：US13003216
申请日：2009-07-07
Applicant: Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
Inventor： Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
IPC: A61K31/519 , C07D491/056
CPC classification number: C07D491/056 , A61K31/519 , C07B2200/13
Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
Abstract translation: 本发明涉及4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐，其新结晶形式，其用于治疗由EGFR激酶介导的疾病及其组合治疗用途的治疗用途 与其他治疗剂。 本发明还提供用于制备4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐的合成方法，其新结晶形式和用于合成4 - [（ -3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐。
-
公开(公告)号：US20130053304A1
公开(公告)日：2013-02-28
申请号：US13643840
申请日：2011-04-29
Applicant: Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
Inventor： Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
IPC: A61K38/26 , A61P3/10 , A61P3/08 , A61P3/04 , A61P9/12 , A61P1/04 , A61P25/00 , A61P9/10 , A61P9/00 , A61P7/02 , A61P1/00 , C07K14/605 , A61P3/06
CPC classification number: C07K14/605 , A61K38/00
Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analogue shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analogue has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analogue is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analogue in conquering blood sugar.
Abstract translation: 本发明提供如下式所示的胰高血糖素样肽-1（GLP-1）类似物，其中X选自甘氨酸和甘氨酰胺。 GLP-1类似物相对于序列GLP-1具有位置8的非蛋白原性氨基酸残基，并且用包含两个酸性基团的部分酰化至位置26的赖氨酸残基。GLP-1类似物对 二肽基肽酶IV，以使体内延长半衰期。 还提供了GLP-1类似物在征服血糖中的用途。
-
Patent Agency Ranking
6.发明申请Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof 有权盐酸伊可啶，合成，结晶形式，药物组合物及其用途公开(公告)号：US20110182882A1
公开(公告)日：2011-07-28
申请号：US13003216
申请日：2009-07-07
Applicant: Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
Inventor： Yinxiang Wang , Guojian Xie , Lieming Ding , Fenlai Tan , Yunyan Hu , Wei He , Bin Han , Wei Long , Yong Liu , Haima Ai , Charles Davis , Don Zhang
IPC: A61K39/395 , C07D491/056 , A61K31/519 , A61K38/43 , A61P35/00
CPC classification number: C07D491/056 , A61K31/519 , C07B2200/13
Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
Abstract translation: 本发明涉及4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐，其新结晶形式，其用于治疗由EGFR激酶介导的疾病及其组合治疗用途的治疗用途 与其他治疗剂。 本发明还提供用于制备4 - [（3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐的合成方法，其新结晶形式和用于合成4 - [（ 3-乙炔基苯基）氨基] -6,7-苯并-12-冠 - 喹唑啉盐酸盐。
-
公开(公告)号：US09409900B2
公开(公告)日：2016-08-09
申请号：US13884470
申请日：2011-11-09
Applicant: Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Yunyan Hu , Fenlai Tan , Yinxiang Wang
Inventor： Xinshan Kang , Wei Long , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Yunyan Hu , Fenlai Tan , Yinxiang Wang
IPC: C07D417/12 , C07D233/88 , C07D405/14 , C07D417/14 , C07D213/74 , C07D213/80 , C07D213/803 , C07D241/20 , C07D277/42 , C07D285/08 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/12 , C07D401/14
CPC classification number: C07D417/14 , C07D213/74 , C07D213/80 , C07D213/803 , C07D233/88 , C07D241/20 , C07D277/42 , C07D285/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D417/12
Abstract: The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders.
Abstract translation: 提供式（I）的化合物，其药学上可接受的盐，其溶剂化物，其螯合物，其非共价络合物或上述化合物的产物或上述任何形式的混合物。 化合物在制备用于治疗和/或预防糖尿病，肥胖症和相关疾病的药物中的用途。
-
8.发明授权公开(公告)号：US09242991B2
公开(公告)日：2016-01-26
申请号：US13809836
申请日：2011-07-14
Applicant: Shaojing Hu , Fei Wang , Wei Long , Xiaoyan Shen , Fenlai Tan , Yinxiang Wang
Inventor： Shaojing Hu , Fei Wang , Wei Long , Xiaoyan Shen , Fenlai Tan , Yinxiang Wang
IPC: A61K31/519 , A61K31/4353 , C07D491/14 , C07D491/04 , C07D498/04
CPC classification number: C07D491/04 , C07D498/04
Abstract: This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder
Abstract translation: 本发明涉及某些新的稠合喹唑啉衍生物（式I）作为c-Met抑制剂，其如式I所示，其合成及其用于治疗c-Met介导的病症的用途。 更具体地，本发明涉及用于c-Met的有用的抑制剂的稠合杂环衍生物，这种化合物的制备方法和作为c-Met介导的病症治疗的方法
-
公开(公告)号：US08951959B2
公开(公告)日：2015-02-10
申请号：US13643840
申请日：2011-04-29
Applicant: Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
Inventor： Yinxiang Wang , Fenlai Tan , Shaojing Hu , Xiangdong Zhao , Cunbo Ma , Yanping Wang , Xiaoyan Shen , Lieming Ding , Yunyan Hu , Hong Cao , Wei Long
IPC: A61K38/00 , A61P9/10 , C07K14/47 , A61P3/04 , A61K38/22 , A61P3/08 , A61P3/10 , A61K38/26 , A61P7/12 , C07K14/605 , A61K38/28 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00
CPC classification number: C07K14/605 , A61K38/00
Abstract: Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar.
Abstract translation: 本发明提供如下式所示的胰高血糖素样肽-1（GLP-1）类似物，其中X选自甘氨酸和甘氨酰胺。 GLP-1类似物相对于序列GLP-1具有位置8的非蛋白原性氨基酸残基，并且用包含两个酸性基团的部分酰化至位置26的赖氨酸残基。GLP-1类似物对 二肽基肽酶IV，以使体内延长半衰期。 还提供了GLP-1类似物在征服血糖中的用途。
-
10.发明申请公开(公告)号：US20140343137A1
公开(公告)日：2014-11-20
申请号：US14166203
申请日：2012-07-30
Applicant: Xinshan Kang , Wei Long , Fei Wang , Cunbo Ma , Liufeng Zhou , Yunyan Hu , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan
Inventor： Xinshan Kang , Wei Long , Fei Wang , Cunbo Ma , Liufeng Zhou , Yunyan Hu , Yanping Wang , Hong Cao , Yinxiang Wang , Fenlai Tan
IPC: C07D311/56
CPC classification number: C07D311/56
Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
Abstract translation: 公开了式I化合物的多晶型物，其制备方法，包括制备中间体，其药物组合物，以及上述多晶型物在制备用于治疗疾病，病症或病症的药物中的用途。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.014 seconds)
